Role of blood urea nitrogen in predicting the post-discharge prognosis in elderly patients with acute decompensated heart failure

Xiaohong Ren, Wei Qu, Lijuan Zhang, Miao Liu, Xuling Gao, Yuting Gao, Xiaodan Cheng, Weiwei Xu & Youhong Liu

Blood urea nitrogen (BUN) is a surrogate marker for neurohormonal activation, but the association between BUN and the post-discharge prognosis in elderly patients with acute decompensated heart failure (ADHF) is not well defined. We explored the association between BUN and post-discharge all-cause mortality in 652 elderly patients (73.9 ± 7.8 yr) with ADHF. All patients were followed for a mean duration of 32 months (12–69 months). BUN was analyzed both as a continuous variable and according to two categories: low BUN group (BUN < 15.35 mmol/L, N = 361) and high BUN group (BUN ≥ 15.35 mmol/L, N = 291). The risk of all-cause mortality increased by 1.6% per 1 mmol/L increase in BUN concentration when BUN was used as a continuous variable [hazard ratio (HR): 1.016, 95% confidence interval (CI): 1.006–1.026, p = 0.002]. BUN maintained an independent and significant positive correlation with all-cause mortality as a categorical variable (HR: 1.355, 95% CI: 1.023–1.794, p = 0.034 for the high BUN group). The BUN C-statistic for predicting all-cause mortality was 0.624 (95% CI: 0.585–0.661). The cut-off value for BUN was 15.35 mmol/L with sensitivity of 0.58 and specificity of 0.63. The prognostic performance of BUN was similar to brain natriuretic peptide (BNP) for predicting all-cause mortality (C-statistic: z = 0.044, p = 0.965). These results suggest that BUN is an independent predictor of post-discharge all-cause mortality in elderly patients with ADHF and its prognostic performance was similar to that of BNP.

Morbidity due to heart failure (HF) is increasing gradually1, and the incidence rate of newly occurring HF is far higher in the elderly population than in the young and middle-aged population2. Elderly patients with HF also have a worse prognosis than young and middle-aged patients3,4. Patients with acute decompensated heart failure (ADHF) usually suffer from high mortality after discharge3,4. Studies have shown that activation of the sympathetic nervous system (SNS), renin-angiotensin-aldosterone system (RAS), arginine vasopressin (AVP) and neurohumors are major pathophysiological changes in patients with HF5,6. The increased activities of the SNS and RAS enhance reabsorption of urea nitrogen by the proximal and distal renal tubules, and the increased secretion of AVP facilitates distribution of the urea transporter in the collecting ducts5,6. Therefore, blood urea nitrogen (BUN) is not only an indicator reflecting renal function, but also an effective marker indicating neurohormonal activation5–7. Previous studies have reported a significant correlation between an increase in BUN and a poor prognosis in patients with acute8–14 and chronic15–17 HF. However, no study has focused on the relationship between BUN and the post-discharge prognosis in elderly patients with ADHF. This study explored the effects of BUN on the post-discharge prognosis in elderly patients with ADHF.

Results

Baseline Characteristics of the Study Population by Clinical Outcome. The final study cohort consisted of 652 elderly patients with ADHF. The cohort was divided into a surviving group [418 patients (64.1%)] and a death group [234 patients (35.9%)]. The clinical characteristics of the two groups are shown in Table 1. The death group had significantly lower percentages of males, New York Heart Association (NYHA) class III, and discharge prescriptions of a β-receptor blocker and spironolactone, compared with the surviving group. Age,
Creatinine, uric acid, BUN, fasting blood glucose, brain natriuretic peptide (BNP), and heart rate were higher in the death group than those in the surviving group. Lower levels of red blood cells, hemoglobin, albumin, prealbumin, cholesterol, low density lipoprotein, serum sodium and ejection fraction were observed in the death group.

Prognostic Performance of BUN and BNP for the Prognosis Prediction. The C-statistics of BUN and BNP for predicting all-cause mortality were 0.624 [95% confidence interval (CI): 0.585–0.661] and 0.625 (95% CI: 0.587–0.662). The cut-off values for BUN and BNP for predicting all-cause mortality were 15.35 mmol/L with sensitivity of 0.58 and specificity of 0.63 and 805 ng/L with sensitivity of 0.67 and specificity of 0.53, respectively (Table 2, Fig. 1). The prognostic performance of BUN was similar to that of BNP (C-statistic: z = 0.044, p = 0.965) (Table 2).

| Variable                        | survival group (n = 418) | death group (n = 234) | Overall (n = 652) | p-value |
|---------------------------------|-------------------------|-----------------------|-------------------|---------|
| **Demographics**                |                         |                       |                   |         |
| Age, yrs                        | 72.4 ± 7.3              | 76.5 ± 8.0            | 73.9 ± 7.8        | <0.001  |
| male                            | 169 (40.4)              | 126 (53.8)            | 295 (45.2)        | 0.001   |
| **Medical history**             |                         |                       |                   |         |
| Ischemia cardiomyopathy         | 99 (23.7)               | 57 (24.7)             | 156 (23.9)        | 0.966   |
| Diabetes Mellitus               | 98 (23.4)               | 60 (25.6)             | 158 (24.2)        | 0.530   |
| Hypertension                    | 250 (59.8)              | 134 (57.3)            | 384 (58.9)        | 0.527   |
| Current smoking                 | 113 (27.0)              | 64 (27.4)             | 177 (27.1)        | 0.930   |
| Atrial fibrillation             | 59 (14.1)               | 32 (13.7)             | 91 (14.0)         | 0.877   |
| Dilated cardiomyopathy          | 19 (4.5)                | 11 (4.7)              | 30 (4.6)          | 0.928   |
| Valvular disease                | 29 (6.9)                | 14 (6.0)              | 0.222             | 0.637   |
| **Clinical Presentation**       |                         |                       |                   |         |
| NYHA class                      |                         |                       |                   | <0.001  |
| III                             | 141 (33.7)              | 28 (12.0)             | 169 (25.9)        |         |
| IV                              | 277 (66.3)              | 206 (88.0)            | 483 (74.1)        |         |
| SBP on admission, mm Hg         | 138.3 ± 25.3            | 138.9 ± 26.9          | 138.5 ± 25.9      | 0.783   |
| DBP on admission, mm Hg         | 81.5 ± 14.5             | 80.2 ± 14.7           | 81.1 ± 14.6       | 0.262   |
| Heart rate on admission, bpm    | 82.2 ± 22.3             | 88.2 ± 20.8           | 84.4 ± 21.9       | 0.001   |
| **Laboratory results on admission** |                       |                       |                   |         |
| Leukocyte count (× 109/L)       | 7.09 ± 2.60             | 7.64 ± 3.13           | 7.29 ± 2.82       | 0.074   |
| Hemoglobin, g/L                 | 125.7 ± 20.2            | 119.2 ± 22.7          | 123.4 ± 21.3      | 0.001   |
| Albumin, g/L                    | 38.0 ± 4.1              | 35.9 ± 4.3            | 37.2 ± 4.3        | <0.001  |
| SGOT, U/L                       | 18 (12, 29)             | 18 (11, 36)           | 18 (12, 32)       | 0.663   |
| SGPT, U/L                       | 22 (16, 37)             | 23 (15, 43)           | 22 (16, 38)       | 0.858   |
| Creatinine, umol/L              | 81 (69, 100)            | 93 (74, 119)          | 84 (70, 106)      | <0.001  |
| Uric acid, umol/L               | 335 (257, 425)          | 370 (272, 488)        | 345 (259, 444)    | 0.001   |
| BUN, mmol/L                     | 13.92 (11.04, 17.82)    | 16.36 (12.72, 23.10)  | 14.64 (11.58, 19.46) | <0.001  |
| Total cholesterol, mmol/L       | 4.45 ± 1.21             | 4.14 ± 1.18           | 4.34 ± 1.21       | 0.001   |
| Low density lipoprotein, mmol/L | 2.67 ± 0.93             | 2.40 ± 0.95           | 2.57 ± 0.94       | 0.001   |
| High density lipoprotein, mmol/L| 1.17 ± 0.37             | 1.14 ± 0.48           | 1.16 ± 0.41       | 0.304   |
| Triglyceride, mmol/L            | 1.42 ± 1.00             | 1.30 ± 1.10           | 1.37 ± 1.03       | 0.177   |
| Fasting blood glucose, mmol/L   | 6.17 ± 1.84             | 6.56 ± 2.20           | 6.31 ± 1.98       | 0.005   |
| Serum potassium, mmol/L         | 4.07 ± 0.53             | 4.12 ± 0.63           | 4.09 ± 0.57       | 0.381   |
| Serum sodium, mmol/L            | 140.1 ± 3.9             | 138.0 ± 5.1           | 139.3 ± 4.5       | <0.001  |
| Troponin-I, ng/mL               | 0.04 (0.01, 0.47)       | 0.07 (0.02, 2.47)     | 0.05 (0.01, 0.83) | 0.548   |
| BNP, ng/L                       | 752 (291, 1576)         | 1167 (607, 2345)      | 891 (343, 1759)   | <0.001  |
| Ejection fraction on admission% | 52.3 ± 12.4             | 48.1 ± 13.2           | 50.8 ± 12.8       | <0.001  |
| **Medical treatment at discharge** |                       |                       |                   |         |
| ACEI/ARB                        | 330 (78.9)              | 183 (78.4)            | 513 (78.7)        | 0.890   |
| Beta-blockers                   | 273 (65.3)              | 129 (55.1)            | 402 (61.7)        | 0.010   |
| Spironolactone                  | 276 (66.0)              | 129 (55.1)            | 405 (62.1)        | 0.006   |

Table 1. Baseline Characteristics of the population by clinical outcome, median (IQR), or N (%), or means ± SD. NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm, beats per minute; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamate-pyruvate transaminase; BUN, blood urea nitrogen; BNP, brain natriuretic peptide; ACEI/ARB, Angiotensin-converting enzyme inhibitors/Angiotensin receptor blockers.

Creatinine, uric acid, BUN, fasting blood glucose, brain natriuretic peptide (BNP), and heart rate were higher in the death group than those in the surviving group. Lower levels of red blood cells, hemoglobin, albumin, prealbumin, cholesterol, low density lipoprotein, serum sodium and ejection fraction were observed in the death group.

Prognostic Performance of BUN and BNP for the Prognosis Prediction. The C-statistics of BUN and BNP for predicting all-cause mortality were 0.624 [95% confidence interval (CI): 0.585–0.661] and 0.625 (95% CI: 0.587–0.662). The cut-off values for BUN and BNP for predicting all-cause mortality were 15.35 mmol/L with sensitivity of 0.58 and specificity of 0.63 and 805 ng/L with sensitivity of 0.67 and specificity of 0.53, respectively (Table 2, Fig. 1). The prognostic performance of BUN was similar to that of BNP (C-statistic: z = 0.044, p = 0.965) (Table 2).
Clinical Characteristics of the Study Population Based on BUN. According to the BUN cut-off value, 652 patients were divided into the low BUN group (BUN < 15.35 mmol/L, N = 361, 55.4%) and the high BUN group (BUN ≥ 15.35 mmol/L, N = 291, 44.6%). The clinical characteristics of the two groups are shown in Table 3. A higher proportion of males, NYHA class IV, and dilated cardiomyopathy were detected in the high BUN group but a lower proportion of hypertension and discharge prescriptions for β-receptor blockers and spironolactone was detected in the high BUN group than in the low BUN group. The high BUN group had lower diastolic and systolic blood pressure at admission and lower hemoglobin, albumin, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, serum sodium, and ejection fraction, but had a higher age, creatinine, uric acid, potassium, and BNP than those in the low BUN group. The mortality rate in the high BUN group was significantly higher than that in the low BUN group during the follow-up (46.4% vs 27.4%, \( p < 0.001 \)).

Prognostic Value of BUN for Determining Clinical Outcome. BUN was significantly predictive of all-cause mortality when used as a continuous variable [hazard ratio (HR): 1.029, 95% CI: 1.020–1.037, \( p < 0.001 \) for per 1 mmol/L increase] in the univariate Cox regression analysis (Table 4). After adjusting for covariates, BUN remained associated with all-cause mortality, with an increased all-cause mortality risk of 1.6% per 1 mmol/L increase in BUN concentration (HR: 1.016, 95% CI: 1.006–1.026, \( p = 0.002 \)) (Table 4).

When categorized into two groups (low BUN group: BUN < 15.35 mmol/L; high BUN group: BUN ≥ 15.35 mmol/L), BUN remained significantly predictive of all-cause mortality (Table 4). In the univariate Cox regression analysis, the high BUN group had a substantially higher risk of all-cause death compared with the low BUN group (HR: 1.959, 95% CI: 1.511–2.541, \( p < 0.001 \)) (Table 4). In the multivariate Cox regression analysis, the high BUN group still conferred a significantly higher all-cause mortality than the low BUN group (HR: 1.355, 95% CI: 1.023–1.794, \( p = 0.034 \)) (Table 4).

BNP independently predicted all-cause mortality in the univariate and multivariate Cox regression analyses (Table 4). However, creatinine was not an independent prognostic factor (Table 4).

Pearson’s correlation analysis revealed that time of death was significantly and negatively correlated with BUN level (\( r = -0.243, p < 0.001 \)) (Fig. 2).

Discussion
The present study tested the association between BUN and post-discharge all-cause mortality in elderly patients with ADHF. The main findings were as follows: (1) BUN was an independent predictor of post-discharge all-cause mortality in elderly patients with ADHF; (2) the prognostic performance of BUN was similar to that of BNP for predicting post-discharge all-cause mortality in elderly patients with ADHF.
BUN is a protein metabolic product of the human body that is synthesized in the liver and excreted by the kidneys. Thus, the BUN level represents the balance between urea production and renal excretion and is an important marker of renal damage. In the past, BUN has only been used to reflect renal function. For the first time, Aronson et al. studied the value of BUN for prognosing patients admitted for ADHF. They found that BUN was an independent predictor of long-term all-cause mortality in patients admitted for ADHF. This observation was verified and extended by other researchers who found that elevated BUN was an independent predictor of adverse outcomes in patients with acute and chronic HF. In addition, BUN was confirmed to be a stronger predictor of adverse outcomes than serum creatinine or estimated glomerular filtration rate (eGFR). However, no study has focused on the relationship between BUN and the post-discharge prognosis in elderly patients with ADHF. Our study confirmed that a high BUN was an independent predictor of all-cause mortality in elderly patients.

### Table 3. Clinical Characteristics of the population by BUN, median (IQR), or N (%), or means ± SD.

| Variable                           | Low BUN group (n = 361) | High BUN group (n = 291) | p-value |
|------------------------------------|-------------------------|--------------------------|---------|
| Demographics                       |                         |                          |         |
| Age, yrs                           | 72.7 ± 7.7              | 75.3 ± 7.7               | <0.001  |
| male                               | 137 (38.0)              | 158 (54.3)               | <0.001  |
| Medical history                    |                         |                          |         |
| Ischemia cardiomyopathy            | 171 (47.4)              | 139 (47.8)               | 0.919   |
| Diabetes Mellitus                  | 85 (23.5)               | 73 (25.1)                | 0.648   |
| Hypertension                       | 229 (63.4)              | 155 (53.3)               | 0.009   |
| Current smoking                    | 99 (27.4)               | 78 (26.8)                | 0.860   |
| Atrial fibrillation                | 47 (13.0)               | 44 (15.1)                | 0.442   |
| Dilated cardiomyopathy             | 11 (3.0)                | 19 (6.5)                 | 0.035   |
| Valvular disease                   | 24 (6.6)                | 19 (6.5)                 | 0.951   |
| Clinical Presentation              |                         |                          |         |
| NYHA class                         |                         |                          | <0.001  |
| III                                | 120 (33.2)              | 49 (16.9)                |         |
| IV                                 | 241 (66.8)              | 242 (83.1)               |         |
| SBP on admission, mm Hg            | 141.2 ± 25.5            | 135.2 ± 26.0             | 0.003   |
| DBP on admission, mm Hg            | 82.5 ± 13.9             | 79.3 ± 15.3              | 0.006   |
| Heart rate on admission, bpm       | 83.0 ± 21.4             | 86.0 ± 22.5              | 0.090   |
| Laboratory results on admission    |                         |                          |         |
| Leukocyte count (× 10^9/L)         | 7.11 ± 2.59             | 7.51 ± 3.07              | 0.148   |
| Hemoglobin, g/L                    | 126.0 ± 18.7            | 120.0 ± 23.8             | 0.001   |
| Albumin, g/L                       | 38.1 ± 4.2              | 36.1 ± 4.1               | <0.001  |
| SGOT, U/L                          | 18 (12, 30)             | 18 (12, 33)              | 0.790   |
| SGPT, U/L                          | 21 (16, 37)             | 24 (16, 43)              | 0.058   |
| Creatinine, umol/L                 | 76 (66, 90)             | 101 (82, 131)            | <0.001  |
| Uric acid, umol/L                  | 308 (237, 398)          | 405 (295, 507)           | 0.001   |
| Total cholesterol, mmol/L          | 4.54 ± 1.12             | 4.09 ± 1.26              | <0.001  |
| Low density lipoprotein, mmol/L    | 2.73 ± 0.96             | 2.37 ± 0.89              | <0.001  |
| High density lipoprotein, mmol/L   | 1.20 ± 0.41             | 1.10 ± 0.41              | 0.002   |
| Triglyceride, mmol/L               | 1.48 ± 1.11             | 1.24 ± 0.91              | 0.003   |
| fasting blood glucose, mmol/L      | 6.33 ± 1.95             | 6.28 ± 2.02              | 0.741   |
| serum potassium, mmol/L            | 3.95 ± 0.45             | 4.26 ± 0.65              | <0.001  |
| serum sodium, mmol/L               | 140.2 ± 3.9             | 138.3 ± 4.9              | <0.001  |
| Troponin-I, ng/mL                  | 0.04 (0.01, 0.71)       | 0.06 (0.02, 0.98)        | 0.897   |
| BNP, ng/L                          | 732 (290, 1455)         | 1168 (506, 2319)         | <0.001  |
| Ejection fraction on admission%    | 53.3 ± 12.1             | 47.7 ± 13.1              | <0.001  |
| Medical treatment at discharge     |                         |                          |         |
| ACEI/ARB                           | 288 (79.8)              | 225 (77.3)               | 0.312   |
| Beta-blockers                      | 247 (68.4)              | 155 (53.3)               | <0.001  |
| Spironolactone                     | 242 (67.0)              | 163 (56.0)               | 0.004   |
| Clinical Outcome                   |                         |                          |         |
| all-cause mortality,%              | 99 (27.4)               | 135 (46.4)               | <0.001  |

BUN is a protein metabolic product of the human body that is synthesized in the liver and excreted by the kidneys. Thus, the BUN level represents the balance between urea production and renal excretion and is an important marker of renal damage. In the past, BUN has only been used to reflect renal function. For the first time, Aronson et al. studied the value of BUN for prognosing patients admitted for ADHF. They found that BUN was an independent predictor of long-term all-cause mortality in patients admitted for ADHF. This observation was verified and extended by other researchers who found that elevated BUN was an independent predictor of adverse outcomes in patients with acute and chronic HF. In addition, BUN was confirmed to be a stronger predictor of adverse outcomes than serum creatinine or estimated glomerular filtration rate (eGFR). However, no study has focused on the relationship between BUN and the post-discharge prognosis in elderly patients with ADHF. Our study confirmed that a high BUN was an independent predictor of all-cause mortality in elderly patients.
patients with ADHF. The risk of all-cause mortality increased by 1.6% per 1 mmol/L increase in BUN concentration when BUN was considered a continuous variable (HR: 1.016, 95% CI: 1.006–1.026, \( p = 0.002 \)). BUN still maintained an independent and significant positive correlation with all-cause mortality as a categorical variable (HR: 1.355, 95% CI: 1.023–1.794, \( p = 0.034 \) for the high BUN group).

The pathophysiological association between BUN and adverse outcomes in patients with HF has been evaluated. First, HF activates the SNS and RAS, which can decrease eGFR and increase tubular urea reabsorption \(^5,6\). The RAS can increase the concentration-dependent reabsorption of urea by the proximal renal tubules, while the SNS can increase flow-dependent reabsorption of urea by the distal renal tubules. Previous studies have reported that BUN levels are correlated with the neurohumoral response \(^7,18,19\). Secondly, more AVP is secreted by patients suffering from HF, resulting in an increased distribution of the urea transporter in the collecting ducts, further causing an increase in urea reabsorption \(^5,6\). Thus, BUN may be a surrogate marker for activation of the SNS, RAS, and AVP.

BNP is a very important biomarker in patients with HF. It is widely recommended for the diagnosis, treatment, and the prognostic prediction of patients with HF \(^20,21\). In this study, both BUN and BNP independently predicted all-cause mortality. BUN was also proven to have the same discriminatory performance as BNP for predicting all-cause mortality (C-statistic: \( z = 0.044, p = 0.965 \)). Taken together, BUN is a very useful clinical parameter to predict the long-term prognosis in elderly patients with ADHF.

Table 4. Effects of multiple variables on Clinical Outcomes in COX regression analysis. *Adjusted for age, gender, heart rate on admission, NYHA class, hemoglobin, albumin, uric acid, creatinine, total cholesterol, low density lipoprotein, fasting blood glucose, serum sodium, BNP, ejection fraction on admission, use of \( \beta \)-receptor blockers and spironolactone.

| Univariate Analysis | Multivariate Analysis |
|---------------------|----------------------|
|                     | HR 95% CI p value | HR 95% CI p value |
| BNP per 1 ng/L increase | 1.000 1.000–1.000 | <0.001 1.000 1.000–1.000 0.001 |
| Creatinine per 1 umol/L increase | 1.000 0.997–1.003 | 0.997 |
| BUN as a continuous variable | 1.029 1.020–1.037 | <0.001 1.016 1.006–1.026 0.002* |
| BUN as a categories variable | 1.959 1.511–2.541 | <0.001 1.355 1.023–1.794 0.034^ |

Figure 2. The correlation between BUN level and time of death.
outcomes in patients with ADHF. Particularly, neurohormonal activation and hemodynamic abnormalities may play a prominent role in patients with ADHF. BUN may increase because of activation of the SNS, RAS and AVP, independently of changes in eGFR.

Conclusions
BUN was an independent predictor of post-discharge all-cause mortality in elderly patients with ADHF. The prognostic performance of BUN was similar to that of BNP.

Methods
Study Design and Setting. This study was based on a retrospective cohort. In total, 670 consecutive elderly patients (age ≥ 60 years, average 73.9 ± 7.8 yr, 59.6% females), who were hospitalized for ADHF at a large hospital in Northeast China (Fourth People's Hospital of Shenyang, Shenyang, China), were included in the cohort from January 2012 to January 2016. ADHF was defined according to guidelines. All patients received standardized HF treatment according to the guidelines. Patients who were receiving regular hemodialysis were excluded (n = 18). The final study cohort consisted of 652 patients. Clinical data of all cases were collected from the electronic medical records. Left ventricular ejection fraction was determined by echocardiography during hospitalization. In all cases, venous blood samples were drawn on admission into standard tubes and measured for BUN using a completely automated biochemistry-immunity analyzer (Ci 16200, Abbott, Abbott Park, IL, USA) in the core laboratory of the hospital. Clinical follow-up was assessed in January 2017 by a hospital visit or a phone interview of the patient's general practitioner/cardiologist, the patient himself, or their family. All patients were followed for a mean duration of 32 months (12–69 months). The clinical endpoint of the study was all-cause mortality, which was identified from the patients' medical records or the patient's referring hospital physician. All events were validated by two independent event-judge physicians. This study complied with the Declaration of Helsinki, and the Fourth People's Hospital of Shenyang Research Ethics Committee approved this research protocol. Written informed consent was formally obtained from all participants.

Statistical Analysis. Quantitative variables are presented as mean ± standard deviation or median (interquartile range), and categorical variables are presented as counts and proportions (%). The Cox proportional-hazards regression model was used to analyze the effect of the variables on event-free survival. Variables showing significance in the univariate analysis (Table 1, p < 0.05) were entered into the final model, including age, gender, heart rate on admission, NYHA class, hemoglobin, albumin, uric acid, creatinine, total cholesterol, low density lipoprotein, fasting blood glucose, serum sodium, BNP, ejection fraction on admission, and use of β-blocker, Aβ-blocker and spironolactone. BUN was analyzed as a continuous and categorical variable. The results are reported as HRs with associated 95% CIs. The predictive performance of BUN and BNP was assessed by an index of discrimination (C-statistic). The C-statistic, which is defined by the area under the receiver operating characteristic curve in relation to all-cause mortality, was compared using a nonparametric test developed by DeLong et al., and MedCalc software for Windows, version 11.4.2.0 (MedCalc Software, Mariakerke, Belgium). Pearson's correlation analysis was conducted to analyze the relationship between BUN level and time of death. All tests were two-sided, and a p-value < 0.05 was considered significant. All statistical analyses were performed with SPSS version 19 software (SPSS Inc., Chicago, IL, USA).

Data Availability
All data generated or analyzed during this study are included in this published article.

References
1. Levy, D. et al. Long-term trends in the incidence of and survival with heart failure. The New England journal of medicine 347, 1397–1402, https://doi.org/10.1056/NEJMoat020265 (2002).
2. Bleumink, G. S. et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25, 1614–1619, https://doi.org/10.1093/eurheartj/ejh161 (2004).
3. Jong, P., Vowinkel, E., Liu, P. P., Gong, Y. & Tu, J. V. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Archives of internal medicine 162, 1689–1694 (2002).
4. Jaagoild, P. et al. Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments. Archives of internal medicine 158, 1081–1089 (1998).
5. Kazory, A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am J Cardiol 106, 694–700, https://doi.org/10.1016/j.amjcard.2010.04.024 (2010).
6. Schrier, R. W. Blood urea nitrogen and serum creatinine: not married in heart failure. Circulation. Heart failure 1, 2–5, https://doi.org/10.1161/circheartfailure.108.770834 (2008).
7. Testani, J. M., Coca, S. G., Shannon, R. P., Kimmel, S. E. & Cappola, T. P. Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials. European journal of heart failure 13, 1224–1230, https://doi.org/10.1093/eurhj/hfl123 (2011).
8. Aronson, D., Mittleman, M. A. & Burger, A. J. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. The American journal of medicine 116, 466–473, https://doi.org/10.1016/j.amjmed.2003.11.014 (2004).
9. Shenkman, H. J., Zareba, W. & Bisognano, J. D. Comparison of prognostic significance of amino-terminal pro-brain natriuretic Peptide versus blood urea nitrogen for predicting events in patients hospitalized for heart failure. Am J Cardiol 99, 1143–1145, https://doi.org/10.1016/j.amjcard.2006.11.050 (2007).
10. Chen, C. Y. et al. Serum blood urea nitrogen and plasma brain natriuretic Peptide and low diastolic blood pressure predict cardiovascular morbidity and mortality following discharge in acute decompensated heart failure patients. Circulation journal: official journal of the Japanese Circulation Society 76, 2372–2379 (2012).
11. Mura, M. et al. Prognostic impact of blood urea nitrogen changes during hospitalization in patients with acute heart failure syndrome. Circulation journal: official journal of the Japanese Circulation Society 77, 1221–1228 (2013).
12. Kajimoto, K., Sato, N. & Takano, T. Relation between elevated blood urea nitrogen, clinical features or comorbidities, and clinical outcome in patients hospitalized for acute heart failure syndromes. *Int J Cardiol* **201**, 311–314, https://doi.org/10.1016/j.ijcard.2015.08.061 (2015).

13. Kajimoto, K., Minami, Y., Sato, N. & Takano, T. Serum sodium concentration, blood urea nitrogen, and outcomes in patients hospitalized for acute decompensated heart failure. *Int J Cardiol* **222**, 195–201, https://doi.org/10.1016/j.ijcard.2016.07.255 (2016).

14. Jujo, K. et al. Persistent high blood urea nitrogen level is associated with increased risk of cardiovascular events in patients with acute heart failure. *ESC Heart failure* **4**, 545–553, https://doi.org/10.1002/ehf2.12188 (2017).

15. Cauthen, C. A. et al. Relation of blood urea nitrogen to long-term mortality in patients with heart failure. *Am J Cardiol* **101**, 1643–1647, https://doi.org/10.1016/j.amjcard.2008.01.047 (2008).

16. Klein, L. et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). *Circulation. Heart failure* **1**, 25–33, https://doi.org/10.1161/circheartfailure.107.746933 (2008).

17. Lombardi, C. et al. Prognostic value of serial measurements of blood urea nitrogen in ambulatory patients with chronic heart failure. *Pannoninerva medica* **58**, 8–15 (2016).

18. Testani, J. M., Cappola, T. P., Brensinger, C. M., Shannon, R. P. & Kimmel, S. E. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. *J Am Coll Cardiol* **58**, 375–382, https://doi.org/10.1016/j.jacc.2011.01.052 (2011).

19. Schrier, R. W. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? *J Am Coll Cardiol* **47**, 1–8, https://doi.org/10.1016/j.jacc.2005.07.067 (2006).

20. Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* **37**, 2129–2200, https://doi.org/10.1093/eurheartj/ehw128 (2016).

21. Yancy, C. W. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation* **136**, e137–e161, https://doi.org/10.1161/cir.0000000000000509 (2017).

22. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* **44**, 837–845 (1988).

**Author Contributions**

Y.L. conceived and designed the experiments. X.R., L.Z., M.L., X.G., Y.G., X.C. and W.X. performed the experiments. X.R. analyzed the data and wrote the paper. W.Q. revised the paper. All authors had reviewed and agreed on the contents of this paper.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018